140 related articles for article (PubMed ID: 2250565)
21. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
22. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
Cesura AM; Kettler R; Imhof R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
[TBL] [Abstract][Full Text] [Related]
23. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
[TBL] [Abstract][Full Text] [Related]
24. Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
Stefanis CN; Alevizos B; Markianos M; Hatzimanolis J
J Neural Transm Suppl; 1988; 26():87-95. PubMed ID: 2452231
[TBL] [Abstract][Full Text] [Related]
25. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.
Berlin I; Saïd S; Spreux-Varoquaux O; Launay JM; Olivares R; Millet V; Lecrubier Y; Puech AJ
Clin Pharmacol Ther; 1995 Oct; 58(4):444-52. PubMed ID: 7586937
[TBL] [Abstract][Full Text] [Related]
26. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
27. Pharmacology of moclobemide.
Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
[TBL] [Abstract][Full Text] [Related]
28. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
29. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
30. Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Villarinho JG; Fachinetto R; de Vargas Pinheiro F; da Silva Sant'Anna G; Machado P; Dombrowski PA; da Cunha C; de Almeida Cabrini D; Pinto Martins MA; Gauze Bonacorso H; Zanatta N; Antonello Rubin M; Ferreira J
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):31-9. PubMed ID: 22525823
[TBL] [Abstract][Full Text] [Related]
31. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase.
Scheinin M; Illi A; Koulu M; Ojala-Karlsson P
Adv Pharmacol; 1998; 42():367-70. PubMed ID: 9327918
[No Abstract] [Full Text] [Related]
32. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
[TBL] [Abstract][Full Text] [Related]
33. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
34. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
[TBL] [Abstract][Full Text] [Related]
38. The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
Rényi L
Br J Pharmacol; 1986 Aug; 88(4):827-35. PubMed ID: 3091132
[TBL] [Abstract][Full Text] [Related]
39. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
Da Prada M; Kettler R; Keller HH; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
[TBL] [Abstract][Full Text] [Related]
40. [Dynamic light-evoked pupillometry for the differentiation of psychotropic substances].
Grünberger J; Linzmayer L; Cepko H; Saletu B
Arzneimittelforschung; 1987 Mar; 37(3):357-60. PubMed ID: 3593452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
